Details of the Drug Combination

General Information of Drug Combination (ID: DCQNNKU)

Drug Combination Name
ERITORAN Apremilast
Indication
Disease Entry Status REF
Community-acquired Pneumonia, Influenza, COVID-19 Phase 3 [1]
Component Drugs ERITORAN   DMKQZ0L Apremilast   DMTWS9E
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ERITORAN
Disease Entry ICD 11 Status REF
Sepsis 1G40-1G41 Phase 3 [2]
ERITORAN Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Toll-like receptor 4 (TLR4) TTISGCA TLR4_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Apremilast
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Approved [3]
Psoriatic arthritis FA21 Approved [4]
Apremilast Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [6]
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Inhibitor [7]
Cyclin-dependent kinase 6 (CDK6) TTO0FDJ CDK6_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Apremilast Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Apremilast Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [10]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02735707) Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4919).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7372).
4 Apremilast FDA Label
5 Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
6 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
7 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
8 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
9 Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695.
10 Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.